{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:25:09Z","timestamp":1776871509478,"version":"3.51.2"},"reference-count":122,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["2020.06766.BD"],"award-info":[{"award-number":["2020.06766.BD"]}]},{"name":"Research Unit on Applied Molecular Biosciences\u2014UCIBIO","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"Research Unit on Applied Molecular Biosciences\u2014UCIBIO","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"Research Unit on Applied Molecular Biosciences\u2014UCIBIO","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"Research Unit on Applied Molecular Biosciences\u2014UCIBIO","award":["2020.06766.BD"],"award-info":[{"award-number":["2020.06766.BD"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["2020.06766.BD"],"award-info":[{"award-number":["2020.06766.BD"]}]},{"name":"FCT","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"FCT","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"FCT","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"FCT","award":["2020.06766.BD"],"award-info":[{"award-number":["2020.06766.BD"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles\u2014solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid\u2013polymer hybrid nanoparticles\u2014have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current \u201cstate-of-the-art\u201d in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.<\/jats:p>","DOI":"10.3390\/pharmaceutics15010216","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T03:25:58Z","timestamp":1673234758000},"page":"216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1247-6738","authenticated-orcid":false,"given":"Ana Camila","family":"Marques","sequence":"first","affiliation":[{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-3398","authenticated-orcid":false,"given":"Paulo C.","family":"Costa","sequence":"additional","affiliation":[{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"given":"S\u00e9rgia","family":"Velho","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology of the University of Porto, R. J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3209-3366","authenticated-orcid":false,"given":"Maria Helena","family":"Amaral","sequence":"additional","affiliation":[{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1021\/acs.bioconjchem.9b00456","article-title":"Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine","volume":"30","author":"Pearce","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20993","DOI":"10.18632\/oncotarget.24772","article-title":"Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles","volume":"9","author":"Engelberg","year":"2018","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1039\/C9BM00931K","article-title":"Antibody-guided nanomedicines as novel breakthrough therapeutic, diagnostic and theranostic tools","volume":"7","author":"Farahavar","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tibs.2009.11.005","article-title":"How antibodies fold","volume":"35","author":"Feige","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2215\/CJN.09430915","article-title":"B cells, antibodies, and more","volume":"11","author":"Hoffman","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2217\/nnm-2017-0043","article-title":"Therapeutic targeting in nanomedicine: The future lies in recombinant antibodies","volume":"12","author":"Pietersz","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1748-0132(07)70083-X","article-title":"Targeted nanoparticles for cancer therapy","volume":"2","author":"Gu","year":"2007","journal-title":"Nano Today"},{"key":"ref_13","first-page":"23","article-title":"High efficiency reduction capability for the formation of Fab\u2019 antibody fragments from F(ab)2 units","volume":"2","author":"Romaschin","year":"2015","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/mab.2015.0036","article-title":"Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application","volume":"34","author":"Khantasup","year":"2015","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","article-title":"Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies","volume":"320","author":"Marques","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2174\/092986712800784667","article-title":"Antibody-conjugated nanoparticles for therapeutic applications","volume":"19","author":"Cardoso","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10611860400010697","article-title":"Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells","volume":"12","author":"Wartlick","year":"2004","journal-title":"J. Drug Target."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ioele, G., Chieffallo, M., Occhiuzzi, M.A., De Luca, M., Garofalo, A., Ragno, G., and Grande, F. (2022). Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules, 27.","DOI":"10.3390\/molecules27175436"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-019-0833-3","article-title":"Nanotechnology in cancer diagnosis: Progress, challenges and opportunities","volume":"12","author":"Zhang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1039\/C8TB00107C","article-title":"Antioxidant activity of nanomaterials","volume":"6","author":"Valgimigli","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","article-title":"Current approaches of nanomedicines in the market and various stage of clinical translation","volume":"12","author":"Shan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2100109","DOI":"10.1002\/anbr.202100109","article-title":"Lipid Nanoparticles for Drug Delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. NanoBiomed Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chaudhuri, A., Kumar, D.N., Shaik, R.A., Eid, B.G., Abdel-Naim, A.B., Md, S., Ahmad, A., and Agrawal, A.K. (2022). Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710068"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100299","DOI":"10.1016\/j.mtadv.2022.100299","article-title":"Fabrication of active targeting lipid nanoparticles: Challenges and perspectives","volume":"16","author":"Menon","year":"2022","journal-title":"Mater. Today Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jmb.2009.12.046","article-title":"Engineering fully human monoclonal antibodies from murine variable regions","volume":"396","author":"Bernett","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26777","DOI":"10.1039\/D0RA03491F","article-title":"A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems","volume":"10","author":"Duan","year":"2020","journal-title":"RSC Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1016\/j.biomaterials.2011.01.048","article-title":"Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor","volume":"32","author":"Kuo","year":"2011","journal-title":"Biomaterials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.colsurfb.2011.02.011","article-title":"Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells","volume":"85","author":"Kuo","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/btpr.2214","article-title":"Conjugation of melanotransferrin antibody on solid lipid nanoparticles for mediating brain cancer malignancy","volume":"32","author":"Kuo","year":"2016","journal-title":"Biotechnol. Prog."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/1061186X.2015.1132223","article-title":"Enhanced delivery of etoposide across the blood-brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles","volume":"24","author":"Kuo","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lfs.2016.01.025","article-title":"Dual targeting of solid lipid nanoparticles grafted with 83-14 MAb and anti-EGF receptor for malignant brain tumor therapy","volume":"146","author":"Kuo","year":"2016","journal-title":"Life Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/mp500737y","article-title":"Tumor-Targeted Delivery of Paclitaxel Using Low Density Lipoprotein-Mimetic Solid Lipid Nanoparticles","volume":"12","author":"Kim","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3109\/21691401.2015.1111226","article-title":"Formulation and optimization of oxaliplatin immuno-nanoparticles using Box-Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer","volume":"44","author":"Tummala","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejps.2018.11.022","article-title":"Surface-tailored anti-HER2\/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells","volume":"128","author":"Souto","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Souto, E.B., Souto, S.B., Zielinska, A., Durazzo, A., Lucarini, M., Santini, A., Horba\u0144czuk, O.K., Atanasov, A.G., Marques, C., and Andrade, L.N. (2020). Perillaldehyde 1,2-epoxide Loaded SLN-Tailored mAb: Production, Physicochemical Characterization and In Vitro Cytotoxicity Profile in MCF-7 Cell Lines. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020161"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2016.10.024","article-title":"Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles","volume":"110","author":"Cavaco","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/21691401.2017.1313267","article-title":"RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: In vitro studies","volume":"46","author":"Siddhartha","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105033","DOI":"10.1016\/j.chemphyslip.2020.105033","article-title":"DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer","volume":"235","author":"Pindiprolu","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.34172\/apb.2021.070","article-title":"DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment","volume":"11","author":"Kumari","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1021\/mp200402e","article-title":"Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody","volume":"8","author":"Liu","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/21691401.2017.1296847","article-title":"Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody","volume":"46","author":"Abdolahpour","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/08982104.2017.1370471","article-title":"Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells","volume":"28","author":"Varshosaz","year":"2018","journal-title":"J. Liposome Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/08982104.2020.1720718","article-title":"Co-delivery of rituximab targeted curcumin and imatinib nanostructured lipid carriers in non-Hodgkin lymphoma cells","volume":"31","author":"Varshosaz","year":"2021","journal-title":"J. Liposome Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109225","DOI":"10.1016\/j.biopha.2019.109225","article-title":"Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin","volume":"118","author":"Guo","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/10717544.2022.2027573","article-title":"Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers","volume":"29","author":"Liu","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"121682","DOI":"10.1016\/j.ijpharm.2022.121682","article-title":"Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression","volume":"618","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"705886","DOI":"10.3389\/fbioe.2021.705886","article-title":"Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol","volume":"9","author":"Nakhaei","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Saman, H., Raza, S.S., Uddin, S., and Rasul, K. (2020). Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers, 12.","DOI":"10.20944\/preprints202004.0400.v1"},{"key":"ref_52","first-page":"7","article-title":"Antiangiogenic therapy for cancer: Current and emerging concepts","volume":"19","author":"Jain","year":"2005","journal-title":"Oncology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/nnm.09.105","article-title":"Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential","volume":"5","author":"Kuesters","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"111832","DOI":"10.1016\/j.msec.2020.111832","article-title":"Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy","volume":"121","author":"Jain","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10517-015-2765-4","article-title":"Site-directed delivery of VEGF-targeted liposomes into intracranial C6 glioma","volume":"158","author":"Shein","year":"2015","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1021\/acs.molpharmaceut.6b00519","article-title":"VEGF- and VEGFR2-targeted liposomes for cisplatin delivery to glioma cells","volume":"13","author":"Shein","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijpharm.2007.04.037","article-title":"Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes","volume":"342","author":"Hatakeyama","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2019.02.001","article-title":"Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer","volume":"560","author":"Lu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2009.07.005","article-title":"Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice","volume":"140","author":"Kim","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijpharm.2015.01.016","article-title":"Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells","volume":"479","author":"Limasale","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"118605","DOI":"10.1016\/j.ijpharm.2019.118605","article-title":"EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers","volume":"569","author":"Matusewicz","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1208\/s12249-020-01671-7","article-title":"EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer","volume":"21","author":"Burande","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2018.05.038","article-title":"Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection","volume":"283","author":"Petrilli","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2015.05.271","article-title":"Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer","volume":"210","author":"Zalba","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"111185","DOI":"10.1016\/j.colsurfb.2020.111185","article-title":"EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells","volume":"194","author":"Eloy","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1871520616666160526103432","article-title":"Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells","volume":"17","author":"Eloy","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2017.02.020","article-title":"Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy","volume":"115","author":"Eloy","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_68","first-page":"1255","article-title":"Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy","volume":"11","author":"Li","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/mp300049n","article-title":"Targeting Her-2+ Breast Cancer Cells with Bleomycin Immunoliposomes Linked to LLO","volume":"9","author":"Kullberg","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1517\/17425247.2013.777425","article-title":"Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel","volume":"10","author":"Raju","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/CAD.0000000000000878","article-title":"Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: Study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)","volume":"31","author":"Rodallec","year":"2020","journal-title":"Anti-Cancer Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10549-013-2667-y","article-title":"Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells","volume":"141","author":"Catania","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jddst.2018.07.017","article-title":"Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes","volume":"47","author":"Amin","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1049\/nbt2.12012","article-title":"Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation","volume":"15","author":"Khaleseh","year":"2021","journal-title":"IET Nanobiotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10611860500206674","article-title":"Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects","volume":"13","author":"Schnyder","year":"2005","journal-title":"J. Drug Target."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.2147\/IJN.S255902","article-title":"In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin","volume":"15","author":"Ashrafzadeh","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.canlet.2015.08.022","article-title":"Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma","volume":"369","author":"Kim","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_78","first-page":"993","article-title":"Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro","volume":"8","author":"Wong","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41598-017-00957-4","article-title":"Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy","volume":"7","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/cbt.28875","article-title":"Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies","volume":"15","author":"Brown","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11095-018-2373-x","article-title":"Anti-GD2 immunoliposomes for targeted delivery of the survivin inhibitor sepantronium bromide (YM155) to neuroblastoma tumor cells","volume":"35","author":"Gholizadeh","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1166\/jbn.2015.2129","article-title":"CD20 antibody-conjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells","volume":"11","author":"Song","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/IJN.S190736","article-title":"Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response","volume":"14","author":"Saeed","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12951-021-00846-z","article-title":"Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model","volume":"19","author":"Merino","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s11671-019-3228-z","article-title":"PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers","volume":"15","author":"Yu","year":"2020","journal-title":"Nanoscale Res. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.msec.2018.04.011","article-title":"Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer","volume":"89","author":"Yang","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.nano.2017.09.012","article-title":"Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes","volume":"14","author":"Wang","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2147\/IJN.S153107","article-title":"Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII","volume":"13","author":"Lu","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Khayrani, A.C., Mahmud, H., Oo, A.K.K., Zahra, M.H., Oze, M., Du, J., Alam, M.J., Afify, S.M., Quora, H.A.A., and Shigehiro, T. (2019). Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051042"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2015.10.044","article-title":"Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin","volume":"220","author":"Arabi","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jsps.2020.09.003","article-title":"Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro","volume":"28","author":"Shamsi","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Scavo, M.P., Cutrignelli, A., Depalo, N., Fanizza, E., Laquintana, V., Gasparini, G., Giannelli, G., and Denora, N. (2020). Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070650"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.drudis.2018.05.033","article-title":"Lipid-polymer hybrid nanocarrier-mediated cancer therapeutics: Current status and future directions","volume":"23","author":"Garg","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/mp900316a","article-title":"Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells","volume":"7","author":"Hu","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/nnm.13.20","article-title":"Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma","volume":"9","author":"Gao","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_96","first-page":"4024","article-title":"Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies","volume":"17","author":"Wei","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10717544.2020.1837294","article-title":"Chemo-immune synergetic therapy of esophageal carcinoma: Trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles","volume":"27","author":"Fu","year":"2020","journal-title":"Drug Deliv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/mp900261m","article-title":"In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen","volume":"7","author":"Simard","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.colsurfb.2014.06.011","article-title":"Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells","volume":"121","author":"Leung","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Limongi, T., Susa, F., Marini, M., Allione, M., Torre, B., Pisano, R., and di Fabrizio, E. (2021). Lipid-Based Nanovesicular Drug Delivery Systems. Nanomaterials, 11.","DOI":"10.3390\/nano11123391"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10717544.2017.1333170","article-title":"Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia","volume":"24","author":"Liu","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"25174","DOI":"10.1021\/acsami.8b08125","article-title":"Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer","volume":"10","author":"Zhai","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/mt.2016.135","article-title":"Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study","volume":"24","author":"Pirollo","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/mt.2016.118","article-title":"A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-018-2207-z","article-title":"Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma","volume":"67","author":"Gargett","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Solomon, B.J., Desai, J., Rosenthal, M., McArthur, G.A., Pattison, S.T., Pattison, S.L., MacDiarmid, J., Brahmbhatt, H., and Scott, A.M. (2015). A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144559"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Elshiaty, M., Schindler, H., and Christopoulos, P. (2021). Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115632"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2019.08.006","article-title":"Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs","volume":"310","author":"Huang","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdh092","article-title":"Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer","volume":"15","author":"Matsumura","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41551-019-0385-4","article-title":"Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models","volume":"3","author":"Kamoun","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kamoun, W., Swindell, E., Pien, C., Luus, L., Cain, J., Pham, M., Kandela, I., Huang, Z.R., Tipparaju, S.K., and Koshkaryev, A. (2020). Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100996"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-15-1518","article-title":"Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer","volume":"76","author":"Espelin","year":"2016","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100365","DOI":"10.1016\/j.esmoop.2021.100365","article-title":"Targeting immunoliposomes to EGFR-positive glioblastoma","volume":"7","author":"Kasenda","year":"2022","journal-title":"ESMO Open"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Hallan, S.S., Sguizzato, M., Esposito, E., and Cortesi, R. (2021). Challenges in the Physical Characterization of Lipid Nanoparticles. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040549"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1021\/acsnano.8b03900","article-title":"Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors","volume":"12","author":"Dai","year":"2018","journal-title":"ACS Nano"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.drudis.2021.04.012","article-title":"Stimuli-responsive hydrogels for intratumoral drug delivery","volume":"26","author":"Marques","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jat.3499","article-title":"Review of the effects of manufactured nanoparticles on mammalian target organs","volume":"38","author":"Wu","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Najahi-Missaoui, W., Arnold, R.D., and Cummings, B.S. (2020). Safe Nanoparticles: Are We There Yet?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010385"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Bukhari, S.I., Imam, S.S., Ahmad, M.Z., Vuddanda, P.R., Alshehri, S., Mahdi, W.A., and Ahmad, J. (2021). Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060840"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:03:20Z","timestamp":1760119400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,8]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["pharmaceutics15010216"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15010216","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,8]]}}}